Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is set to announce its earnings results after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Arena Pharmaceuticals (NASDAQ:ARNA) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.03). The firm had revenue of $6.49 million for the quarter, compared to the consensus estimate of $5.58 million. Arena Pharmaceuticals had a negative net margin of 16.27% and a negative return on equity of 49.87%. The company’s revenue for the quarter was down 31.8% on a year-over-year basis. During the same period last year, the firm earned ($1.10) earnings per share. On average, analysts expect Arena Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) opened at $28.56 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 3.06 and a current ratio of 3.21.

ARNA has been the topic of several research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $37.00 target price on shares of Arena Pharmaceuticals in a research report on Monday, September 25th. Citigroup Inc raised their target price on Arena Pharmaceuticals from $23.00 to $37.00 and gave the stock a “buy” rating in a research report on Tuesday, July 11th. BidaskClub raised Arena Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, July 7th. Needham & Company LLC reissued a “hold” rating on shares of Arena Pharmaceuticals in a research report on Tuesday, August 8th. Finally, Wells Fargo & Company reissued a “market perform” rating and issued a $19.00 target price (up from $15.00) on shares of Arena Pharmaceuticals in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $36.00.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

Arena Pharmaceuticals Company Profile

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Earnings History for Arena Pharmaceuticals (NASDAQ:ARNA)

Receive News & Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.